Paul Matteis
Stock Analyst at Stifel
(3.01)
# 1,435
Out of 5,067 analysts
122
Total ratings
45%
Success rate
0.06%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLT MapLight Therapeutics | Initiates: Buy | $28 | $13.00 | +115.38% | 1 | Nov 21, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Hold | $2 → $3 | $2.16 | +38.89% | 3 | Nov 17, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Hold | $73 → $61 | $55.50 | +9.91% | 11 | Nov 6, 2025 | |
| BIIB Biogen | Upgrades: Buy | $144 → $202 | $176.82 | +14.24% | 7 | Nov 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $455 → $445 | $424.00 | +4.95% | 20 | Nov 4, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $174 → $183 | $141.25 | +29.56% | 10 | Oct 29, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $441 → $495 | $434.23 | +13.99% | 15 | Oct 6, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Hold | $43 → $67 | $78.52 | -14.67% | 6 | Oct 6, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Buy | $27 | $16.14 | +67.29% | 1 | Oct 6, 2025 | |
| PEPG PepGen | Maintains: Buy | $9 → $12 | $5.79 | +107.25% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $65 | $27.78 | +133.98% | 2 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $36 | $21.67 | +66.13% | 4 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $94 | $106.58 | -11.80% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $44.18 | -27.57% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $14.58 | +119.48% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $5.18 | +112.36% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.28 | +212.50% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $13.30 | -24.81% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $20.44 | +193.54% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $28.20 | +27.66% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $28.32 | +23.59% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $23.90 | -12.13% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $10.36 | +179.92% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $9.99 | +100.20% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.72 | +154.24% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $360 → $50 | $4.42 | +1,032.50% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $13.36 | +139.52% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.70 | +1,488.24% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $22.92 | -38.92% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $7.46 | +757.91% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $220.25 | +54.37% | 1 | Dec 21, 2016 |
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $28
Current: $13.00
Upside: +115.38%
Neumora Therapeutics
Nov 17, 2025
Maintains: Hold
Price Target: $2 → $3
Current: $2.16
Upside: +38.89%
BioMarin Pharmaceutical
Nov 6, 2025
Downgrades: Hold
Price Target: $73 → $61
Current: $55.50
Upside: +9.91%
Biogen
Nov 6, 2025
Upgrades: Buy
Price Target: $144 → $202
Current: $176.82
Upside: +14.24%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Hold
Price Target: $455 → $445
Current: $424.00
Upside: +4.95%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $174 → $183
Current: $141.25
Upside: +29.56%
Alnylam Pharmaceuticals
Oct 6, 2025
Maintains: Buy
Price Target: $441 → $495
Current: $434.23
Upside: +13.99%
Ionis Pharmaceuticals
Oct 6, 2025
Maintains: Hold
Price Target: $43 → $67
Current: $78.52
Upside: -14.67%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Buy
Price Target: $27
Current: $16.14
Upside: +67.29%
PepGen
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $5.79
Upside: +107.25%
Sep 24, 2025
Maintains: Buy
Price Target: $30 → $65
Current: $27.78
Upside: +133.98%
Jul 31, 2025
Maintains: Buy
Price Target: $66 → $36
Current: $21.67
Upside: +66.13%
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $106.58
Upside: -11.80%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $44.18
Upside: -27.57%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $14.58
Upside: +119.48%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $5.18
Upside: +112.36%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.28
Upside: +212.50%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $13.30
Upside: -24.81%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $20.44
Upside: +193.54%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $28.20
Upside: +27.66%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $28.32
Upside: +23.59%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $23.90
Upside: -12.13%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $10.36
Upside: +179.92%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $9.99
Upside: +100.20%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $4.72
Upside: +154.24%
Jun 23, 2022
Downgrades: Hold
Price Target: $360 → $50
Current: $4.42
Upside: +1,032.50%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $13.36
Upside: +139.52%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.70
Upside: +1,488.24%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $22.92
Upside: -38.92%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $7.46
Upside: +757.91%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $220.25
Upside: +54.37%